Hypophosphatemia in children treated with ferric carboxymaltose
In adults, iron‐induced hypophosphatemia is an increasingly recognized adverse drug reaction of certain high‐dose intravenous iron formulations, particularly ferric carboxymaltose (FCM) (1‐3). Data in children are sparse, but severe hypophosphatemia has been reported in adolescents receiving FCM treatment (4). The aims of this study were to determine the incidence of hypophosphatemia in a larger pediatric collective receiving FCM for treatment of iron deficiency anemia and to evaluate potential gender differences.
No comments:
Post a Comment